Market Overview

ISI Reiterates Buy, $120 PT On Biogen

International Strategy & Investment Group (ISI) reiterated a buy rating and $120 price target on biotech firm Biogen Idec (Nasdaq: BIIB) today. The price target implies only limited upside for the stock. The stock is up half a percent today.

Posted-In: Analyst Color News Price Target Reiteration Intraday Update Markets Analyst Ratings Trading Ideas

 

Related Articles (ISI + BIIB)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters